Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

NCT00350948 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

244

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Ovarian Neoplasms

Interventions

DRUG: Telcyta
DRUG: Liposomal Doxorubicin

Sponsor

Telik